One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study

One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study

AIM: To assess the effectiveness and safety of ranibizumab 0.5 mg in Taiwanese patients with polypoidal choroidal vasculopathy (PCV) by performing a retrospective exploratory subgroup analysis of the REAL study. METHODS: REAL was a 12-month, observational, prospective, non-interventional phase IV p...

Full description

Bibliographic Details
Main Authors: San-Ni Chen, Cheng-Kuo Cheng, Ling Yeung, Jiann-Torng Chen, Wei-Chun Chan, Jorn-Hon Liu, Shwu-Jiuan Sheu, Wen-Chuan Wu, Chi-Chun Lai
Format: Article
Language:English
Published: Press of International Journal of Ophthalmology (IJO PRESS) 2018-11-01
Series:International Journal of Ophthalmology
Subjects:
observational study
polypoidal choroidal vasculopathy
ranibizumab
Taiwan
visual acuity
Online Access:http://www.ijo.cn/en_publish/2018/11/20181111.pdf

Internet

http://www.ijo.cn/en_publish/2018/11/20181111.pdf

Similar Items